
Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond 177Lu-PSMA-617, which is covered elsewhere...
Like
Save
Share